These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 38048621)

  • 1. Systemic lupus erythematosus patients have unique changes in serum metabolic profiles across age associated with cardiometabolic risk.
    Jury EC; Peng J; Van Vijfeijken A; Martin Gutierrez L; Woodridge L; Wincup C; Pineda-Torra I; Ciurtin C; Robinson GA
    Rheumatology (Oxford); 2024 Oct; 63(10):2741-2753. PubMed ID: 38048621
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased apolipoprotein-B:A1 ratio predicts cardiometabolic risk in patients with juvenile onset SLE.
    Robinson GA; Waddington KE; Coelewij L; Peng J; Naja M; Wincup C; Radziszewska A; Peckham H; Isenberg DA; Ioannou Y; Ciurtin C; Pineda-Torra I; Jury EC
    EBioMedicine; 2021 Mar; 65():103243. PubMed ID: 33640328
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiometabolic and immune factors associated with increased common carotid artery intima-media thickness and cardiovascular disease in patients with systemic lupus erythematosus.
    Ammirati E; Bozzolo EP; Contri R; Baragetti A; Palini AG; Cianflone D; Banfi M; Uboldi P; Bottoni G; Scotti I; Pirillo A; Grigore L; Garlaschelli K; Monaco C; Catapano AL; Sabbadini MG; Manfredi AA; Norata GD
    Nutr Metab Cardiovasc Dis; 2014 Jul; 24(7):751-9. PubMed ID: 24787906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modulation of Cardiometabolic Disease Markers by Type I Interferon Inhibition in Systemic Lupus Erythematosus.
    Casey KA; Smith MA; Sinibaldi D; Seto NL; Playford MP; Wang X; Carlucci PM; Wang L; Illei G; Yu B; Wang S; Remaley AT; Mehta NN; Kaplan MJ; White WI
    Arthritis Rheumatol; 2021 Mar; 73(3):459-471. PubMed ID: 32909675
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Longitudinal Evaluation of Lipoprotein Variables in Systemic Lupus Erythematosus Reveals Adverse Changes with Disease Activity and Prednisone and More Favorable Profiles with Hydroxychloroquine Therapy.
    Durcan L; Winegar DA; Connelly MA; Otvos JD; Magder LS; Petri M
    J Rheumatol; 2016 Apr; 43(4):745-50. PubMed ID: 26834214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-density lipopoprotein antioxidant capacity, subpopulation distribution and paraoxonase-1 activity in patients with systemic lupus erythematosus.
    Gaál K; Tarr T; Lőrincz H; Borbás V; Seres I; Harangi M; Fülöp P; Paragh G
    Lipids Health Dis; 2016 Mar; 15():60. PubMed ID: 27004558
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum metabolomic profiling in patients with systemic lupus erythematosus by GC/MS.
    Yan B; Huang J; Zhang C; Hu X; Gao M; Shi A; Zha W; Shi L; Huang C; Yang L
    Mod Rheumatol; 2016 Nov; 26(6):914-922. PubMed ID: 26915395
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early life infection and proinflammatory, atherogenic metabolomic and lipidomic profiles in infancy: a population-based cohort study.
    Mansell T; Saffery R; Burugupalli S; Ponsonby AL; Tang MLK; O'Hely M; Bekkering S; Smith AAT; Rowland R; Ranganathan S; Sly PD; Vuillermin P; Collier F; Meikle P; Burgner D;
    Elife; 2022 May; 11():. PubMed ID: 35535496
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ¹H NMR-based metabolomic study of metabolic profiling for systemic lupus erythematosus.
    Ouyang X; Dai Y; Wen JL; Wang LX
    Lupus; 2011 Nov; 20(13):1411-20. PubMed ID: 21976403
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Urinary metabolomic profiling of a cohort of Colombian patients with systemic lupus erythematosus.
    Rojo-Sánchez A; Carmona-Martes A; Díaz-Olmos Y; Santamaría-Torres M; Cala MP; Orozco-Acosta E; Aroca-Martínez G; Pacheco-Londoño L; Navarro-Quiroz E; Pacheco-Lugo LA
    Sci Rep; 2024 Apr; 14(1):9555. PubMed ID: 38664528
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibodies to apolipoprotein A-I, high-density lipoprotein, and C-reactive protein are associated with disease activity in patients with systemic lupus erythematosus.
    O'Neill SG; Giles I; Lambrianides A; Manson J; D'Cruz D; Schrieber L; March LM; Latchman DS; Isenberg DA; Rahman A
    Arthritis Rheum; 2010 Mar; 62(3):845-54. PubMed ID: 20131231
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fecal Metabolites Were Altered, Identified as Biomarkers and Correlated With Disease Activity in Patients With Systemic Lupus Erythematosus in a GC-MS-Based Metabolomics Study.
    Yan R; Jiang H; Gu S; Feng N; Zhang N; Lv L; Liu F
    Front Immunol; 2020; 11():2138. PubMed ID: 33013903
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship of serum and dietary vitamin D with high cardiometabolic risk in Mexican systemic lupus erythematosus patients: A cross-sectional study.
    Ruiz-Ballesteros AI; Betancourt-Núñez A; Meza-Meza MR; Rivera-Escoto M; Mora-García PE; Pesqueda-Cendejas K; Vizmanos B; Parra-Rojas I; Campos-López B; Montoya-Buelna M; Cerpa-Cruz S; De la Cruz-Mosso U
    Lupus; 2024 Jul; 33(8):851-863. PubMed ID: 38709772
    [No Abstract]   [Full Text] [Related]  

  • 14. Role of long non-coding RNAs expression (ANRIL, NOS3-AS, and APOA1-AS) in development of atherosclerosis in Egyptian systemic lupus erythematosus patients.
    Abd-Elmawla MA; Fawzy MW; Rizk SM; Shaheen AA
    Clin Rheumatol; 2018 Dec; 37(12):3319-3328. PubMed ID: 30128915
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-density lipoprotein functionality in systemic lupus erythematosus.
    Ganjali S; Shirmohammadi L; Read MI; Sahebkar A
    Semin Arthritis Rheum; 2020 Aug; 50(4):769-775. PubMed ID: 32531506
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hydroxychloroquine increased cholesterol transfer to high-density lipoprotein in systemic lupus erythematosus: A possible mechanism for the reversal of atherosclerosis in the disease.
    Lang MG; Vinagre CG; Bonfa E; Freitas FR; Pasoto SG; Brito TS; Seguro LP; Maranhão RC; Borba EF
    Lupus; 2022 May; 31(6):659-665. PubMed ID: 35332823
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic disturbances associated with systemic lupus erythematosus.
    Wu T; Xie C; Han J; Ye Y; Weiel J; Li Q; Blanco I; Ahn C; Olsen N; Putterman C; Saxena R; Mohan C
    PLoS One; 2012; 7(6):e37210. PubMed ID: 22723834
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GlycA, a novel marker of inflammation, is elevated in systemic lupus erythematosus.
    Chung CP; Ormseth MJ; Connelly MA; Oeser A; Solus JF; Otvos JD; Raggi P; Stein CM
    Lupus; 2016 Mar; 25(3):296-300. PubMed ID: 26637290
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Altered lipoproteins in patients with systemic lupus erythematosus are associated with augmented oxidative stress: a potential role in atherosclerosis.
    Park JK; Kim JY; Moon JY; Ahn EY; Lee EY; Lee EB; Cho KH; Song YW
    Arthritis Res Ther; 2016 Dec; 18(1):306. PubMed ID: 28038677
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolomic profiling reveals serum L-pyroglutamic acid as a potential diagnostic biomarker for systemic lupus erythematosus.
    Zhang Q; Li X; Yin X; Wang H; Fu C; Wang H; Li K; Li Y; Zhang X; Liang H; Li K; Li H; Qiu Y
    Rheumatology (Oxford); 2021 Feb; 60(2):598-606. PubMed ID: 32259244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.